Letter to the Editor

Serum Ferritin is an independent risk factor for Acute Respiratory Distress Syndrome in COVID-19

Dear Editor,

Identifying the significant parameters for early progression toward worse prognosis is fundamental for the management of COVID-19 patients.

In this Journal, Zhi Lin and colleagues[1] recently reported that Chinese patients with severe Sars-CoV2 disease showed higher levels of serum ferritin than patients with not severe one, confirming data from other authors on Chinese[2,3] and Caucasian populations.[4,5]

Here we aimed to establish the most suitable panel for routine prognostic serum laboratory testing in COVID-19 patients upon first admission to the Emergency Department.

We thus enrolled 141 patients (59 females and 82 males, aging $64,48 \pm 16,58$ years) diagnosed as COVID-19 by means of real-time polymerase chain reaction testing and admitted to the isolation ward of Emergency Department at Policlinico Umberto I Hospital in Rome, Italy, between March 2020 and June 2020. Serum samples were collected from patients upon admission before starting any treatment and tested by Laboratory Department.

Of all patients included, 81 patients (57%) showed mild disease (control group) and 60 (43%) showed acute respiratory distress syndrome (ARDS) and systemic inflammation (severe group). Fig. 1A shows the differences in the baseline characteristics between severe and non-severe COVID-19 patients. The severe patients were older and more frequently males and showed significant higher levels of C Reactive Protein (CRP), D-Dimer (D-D), Lactate Dehydrogenase (LDH), Neutrophil to Lymphocyte ratio (NLR) and Ferritin.

Serum ferritin levels were positively correlated with severity of COVID-19 (Fig. 1B) and hyperferritinemia (ferritin level > 500 µg/L), was observed in all patients with severe disease on admission. Moreover, ROC curve analysis confirmed the excellent prognostic accuracies of serum Ferritin in discriminate patients with severe clinical conditions. (AUC 0.939, CI: 0,894 to 0,985 $p < 0.001$) (Fig. 1C).

The triaging of COVID-19 patients is based on a combination of clinical, laboratory and instrumental parameters, mainly represented by Computed Tomography (CT). Thus, based on the severity of pulmonary impairment in CT scan and respiratory failure in need of mechanical ventilation, patients were further divided in 4 groups according to the WHO guidelines updated in May 2020[6]: 29 patients with no CT alterations (Group 0-mild); 32 patients with changes in CT scan no oxygen (Group 1-moderate); 38 patients with CT scan plus oxygen (Group 2-severe) and 42 patients with CT abnormalities plus intensive care unit (ICU) admission (critical-Group 3).

Our data strongly confirm that increased levels of ferritin were directly related with the disease severity (Fig 2A). Particularly, not only severe group showed 2.6 times higher ferritin levels than the mild group, but patients who needed admission to the ICU showed 5.8 times higher ferritin compared to patients with mild COVID-19. Among all parameters considered, we also noted that the NLR was statistically correlated with the severity of disease. (Fig. 2B). Conversely, D-D, LDH and CRP increased only in the group of critical patients (group 3), being substantially stable in the other groups characterized by mild, moderate and severe disease (Fig. 2, panel C, D, E).

Multivariate logistic regression model adjusted for several disease-related risk factors at admission, including age, sex, NLR, D-D, LDH, ferritin and CRP, demonstrated that serum ferritin resulted as an independent predictor of disease severity in COVID-19 patients (OR = 1,0048, 95% CI, 1,0029 to 1,0083, $p < 0,001$.).

If patients were grouped according to the serum ferritin level with a cut off of 500 µg/ml derived from the HLH-2004[7] criterion, hyperferritinemia accounted for 48,22% (68/141) of patients and the hyperferritinemia group had a higher proportion of severe cases (77,94% vs 10,30%, $p < 0,001$) than patients without hyperferritinemia.

This is the first Italian report about the prognostic value of laboratory biomarkers considering 4 groups of mild, moderate, severe and critical patients with COVID-19. We clearly demonstrated that serum levels of ferritin progressively increased with the severity of disease and correlate with poor prognosis in COVID-19 patients.

Increased ferritin levels could be indicative of a strong inflammatory reaction in COVID-19 and recent studies suggest that increased levels of circulating ferritin levels play a critical role by contributing to the development of a cytokine storm[8,9] resembling macrophage activating syndrome.[10] Timely control of the cytokine storm in its early stage through immunomodulators and cytokine antagonists, as well as the reduction of lung inflammatory cell infiltration, is the key to improving the treatment success rate and reducing the mortality rate of patients with COVID-19. In this regard, ferritin evaluation could be an early, available and easy to use screening tool to assess the disease severity at the first admission in the emergency department. This test might be of crucial importance for the timely identification of patients at higher risk of an adverse outcome.

A

Groups Variables [Mean(Std. Dev.)]	mild cases (81patients)	Severe cases (60 patients) p value	
SEX			
male	37 (45,7%)	44 (73,35)	<0,001
female	44(54,3%)	16 (26,7%)	<0,001
Age years	61,11(18,12)	69,16(12,92)	<0,005
FERRITIN µg/L	303(224)	1509(968)	<0,001
NLR	6,86(6,85)	10,88(9,84)	<0,005
D-D ug/dL	1672(1569)	2357(1581)	<0,05
LDH UI/L	286(135)	403(192)	<0,005
CRP mg/dL	6,70(8,29)	11,86(10,77)	<0,05
Albumin g/dL	3,28(0,52)	2,79(0,61)	<0,01
Fibrinogen mg/dL	465(138)	503(111)	ns
Platelet x10³/µL	251(110)	25181319	ns
Troponin µg/L	0,06 (0,12)	0,08(0,11)	ns
Pro-calcitonin µg/L	0,34(0,37)	0,81(0,71)	ns

B

C

AUC = 0,939
P < 0,001

		Analysis of Variance							
Variable		SS Effect	df Effect	MS Effect	SS Error	df Error	MS Error	F	p
FERRITIN µg/L		50184923	1	50184923	59285842	139	426516,8	117,6622	0,000000

Fig. 1. 1A) Characteristics of the study population; 1B) Analysis of Variance of serum ferritin between severe (60) and non severe COVID-19 patients (81); 1C) ROC curve analysis of serum ferritin levels for the severity of COVID-19.

G	Groups					
Variables [Mean(Std. Dev.)]	**0 - mild** (29 patients)	**1 - moderate** (32 patients)	**2 - Severe** (38 patients)	**3 - Critical** (42 patients)	**All** (141 patients)	p value
FERRITIN µg/L	281(323)	308(190)	741(544)	1640(1094)	816(884)	<0,001
NLR	5,48(6,67)	7,32(6,03)	8,73(8,72)	11,47(10,03)	8,62(8,49)	<0,05
D-D ug/dL	1335(1583)	1983(1597)	1749(1369)	2594(1688)	1942(1602)	<0,05
LDH UI/L	285(143)	311(138)	289(124)	744(1366)	395(666)	ns
CRP mg/dL	4,69(9,79)	8,57(8,74)	8,63(8,60)	12,36(10,42)	8,90(9,73)	<0,05
AGE years	52,37(19,88)	65,87(17,16)	65,23(13,63)	71(11,60)	64,48(16,57)	<0,01

Fig. 2. 2A–F) Analysis of Variance – Categorized box and whisker plot of ferritin, NLR, DD, LDH, CRP and age according to COVID-19 severity; 2 G) Analysis of Variance and concentrations of ferritin, NLR, D-D, LDH, CRP and age according to COVID-19 severity.

References

1. Lin Z, Long F, Yang Y. Serum ferritin as an independent risk factor for severity in COVID-19 patients. *J Infect* 2020 Jun 24 Epub ahead of print. doi:10.1016/j.jinf.2020.06.053.
2. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020.
3. Henry BM, de Oliveira M, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med* 2020.
4. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK. Covid-19 in critically ill patients in the Seattle region - case series. *N Engl J Med* 2020. doi:10.1056/NEJMoa2004500.
5. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020;**368**:m606. doi:10.1136/bmj.m606.
6. Clinical management of COVID-19 - interim guidance (May 2020)-WHO - https://reliefweb.int/sites/reliefweb.int/files/resources/2005_clinical_management_of_covid-19-v7.pdf
7. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2007;**48**(2):124–31. doi:10.1002/pbc.21039.
8. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *Int Immunol* 2017;**29**(9):401–9.
9. Wessling-Resnick M. Crossing the iron gate: why and how transferrin receptors mediate viral entry. *Annu Rev Nutr* 2018;**38**:431–58.
10. Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. *Autoimmun Rev* 2020:102538.

O. Gandini*

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

A. Criniti

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

L. Ballesio

Department of Radiology, Anatomo- Pathology and Oncology, Sapienza University of Rome, Rome, Italy

S. Giglio

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

G. Galardo

Medical Emergency Unit, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy

W. Gianni

II Division of Internal Medicine and Geriatrics, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy

L. Santoro, A. Angeloni, C. Lubrano

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

*Corresponding author.
E-mail address:* orietta.gandini@uniroma1.it (O. Gandini)